All In Biotech

Free tool

FAERS Monitor: Neuraceq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204677 or its brand name (Neuraceq, Florbetaben F-18). Reports on generic versions are filed under their own applications.

Reports

21

Serious

5

24% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • amyloid related imaging abnormality-oedema/effusion6
  • burning sensation4
  • injection site pain4
  • asthenia3
  • fatigue3
  • infusion related reaction3
  • discomfort2
  • dizziness2
  • dyspnoea2
  • headache2
  • hyperhidrosis2
  • nausea2
  • accidental underdose1
  • amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits1
  • aphasia1

Reports by year received

View as table
YearReports
20151
20237
20242
20256
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amyloid related imaging abnormality-oedema/effusionSignal64914.62493.424,647
amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits1935.2138.0233
accidental underdose169.610.316
burning sensationSignal457.123.7169
infusion related reactionSignal345.315.990
aphasia133.24.97
discomfort232.88.834
hyperhidrosis215.64.215
injection site painSignal413.15.434
astheniaSignal38.02.812
dizziness24.01.12
fatigue33.91.44
dyspnoea23.50.92
headache23.20.91
nausea22.50.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.